Search

Your search keyword '"Claudia Pop Stanciu"' showing total 3 results
Start Over Author "Claudia Pop Stanciu"
3 results on '"Claudia Pop Stanciu"'

1. Restin protein expression in non‐small cell lung cancer

Author

Frank Aboubakar Nana, Virginie Lamberts, Delphine Hoton, Claudia Pop Stanciu, Marylène Lecocq, François M. Carlier, Fabrice Duplaquet, Lionel Pirard, Charles Pilette, Benoît Bihin, and Sebahat Ocak

Subjects
expression, immunohistochemistry, NSCLC, prognosis, restin, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background Restin is a member of the melanoma‐associated antigen (MAGE) superfamily. Its expression has been reported to be up‐ or downregulated in cancer. Preclinical data suggest it is a tumor suppressor. In this study, we aimed to evaluate restin expression and prognostic value in non‐small cell lung cancer (NSCLC). Methods Restin expression was analyzed by immunohistochemistry in three tissue microarrays consisting of formalin‐fixed/paraffin‐embedded NSCLC specimens from 113 patients, represented in triplicate. Restin staining H‐score was the result of the staining intensity (0‐no, 1‐weak, 2‐moderate, and 3‐strong) multiplied by the percentage of stained tumor cells; it was defined as low if 1–100, moderate if 101–200, and strong if 201–300. Haverage‐score was the average H‐score in the triplicate. Restin Haverage‐scores were tested for correlations with clinical and pathological characteristics and patient outcome. Results Restin expression was localized to the cytoplasm, with nuclear enhancement, of 112/113 (99.1%) NSCLCs. Restin Haverage‐scores were 0 in 1/113 (0.88%), low in 15/113 (13.3%), moderate in 48/113 (42.5%), and strong in 49/113 (43.4%) NSCLCs. Restin Haverage‐scores did not correlate with NSCLC histological subtype, disease stage, recurrence/progression‐free, or overall survival. Conclusion Restin is moderately to strongly expressed in the majority of NSCLC tumors but its expression has no prognostic value in patients with NSCLC.

Published
2023
Full Text
View/download PDF

2. Case report: BRAF A598-T599insV mutation as a potential resistance mechanism to alectinib in ALK-rearranged lung adenocarcinoma

Author

Thomas Pasau, Els Wauters, Isabelle Wauters, Fabrice Duplaquet, Lionel Pirard, Claudia Pop-Stanciu, Nicky D’Haene, Michael Dupont, Thierry Vander Borght, Benoît Rondelet, Sebahat Ocak, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service de pneumologie, UCL - (MGD) Service d'anatomie pathologique, UCL - (MGD) Service de médecine nucléaire, UCL - (MGD) Service de chirurgie cardio-vasculaire et thoracique, UCL - (MGD) Service de radiologie - résonance magnétique, and UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie

Subjects
Cancer Research, Oncology, ALK rearrangement, lung adenocarcinoma, non-small cell lung cancer, resistance to alectinib, BRAF A598-T599insV mutation
Abstract

Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) have improved the prognosis of advanced-stage non-small cell lung cancer (NSCLC) with ALK rearrangement, but resistance mechanisms limit their efficacy. We describe the case of a 63-year-old man with a stage cIVA ALK-rearranged lung adenocarcinoma who developed a BRAF A598-T599insV mutation as a potential resistance mechanism to alectinib, a second-generation ALK TKI. He was treated with an association of BRAF and MEK inhibitors but death occurred two months after treatment initiation in a context of tumor progression and toxicity. Based on this first report of BRAF A598-T599insV mutation occurring in lung cancer, we discuss resistance mechanisms to ALK TKIs, implications of BRAF mutation in NSCLC, and BRAF A598-T599insV mutation in other cancers.

Published
2022

3. Complete tumor response of a locally advanced lung large-cell neuroendocrine carcinoma after palliative thoracic radiotherapy and immunotherapy with nivolumab

Author

Vincent Remouchamps, Claudia Pop-Stanciu, Myriam Remmelink, Marie Wanet, Lionel Pirard, Michaël Dupont, Charlotte Mauclet, Nicky D'Haene, Suzan Lambin, Benoît Rondelet, Thierry Vander Borght, Fabrice Duplaquet, Sebahat Ocak, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service de pneumologie, UCL - (MGD) Service d'oncologie médicale, UCL - (MGD) Service de chirurgie cardio-vasculaire et thoracique, UCL - (MGD) Service de radiologie - résonance magnétique, UCL - (MGD) Service d'anatomie pathologique, UCL - (MGD) Service de médecine nucléaire, and UCL - (MGD) Autre

Subjects
0301 basic medicine, Pulmonary and Respiratory Medicine, Oncology, Adult, Cancer Research, medicine.medical_specialty, Lung Neoplasms, medicine.medical_treatment, Thoracic radiotherapy, Locally advanced, Tumor response, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Positron Emission Tomography Computed Tomography, Locally advanced stage, Antineoplastic Combined Chemotherapy Protocols, medicine, Carcinoma, Humans, Salvage surgery, Neoplasm Metastasis, Neoplasm Staging, Lung, business.industry, Palliative Care, Immunotherapy, medicine.disease, Lung large-cell neuroendocrine carcinoma, Combined Modality Therapy, Immunohistochemistry, Carcinoma, Neuroendocrine, PD-1 inhibitor, Radiation therapy, 030104 developmental biology, medicine.anatomical_structure, Nivolumab, 030220 oncology & carcinogenesis, Synergistic effect, Carcinoma, Large Cell, Female, Radiotherapy, Adjuvant, Human medicine, business
Abstract

Lung large-cell neuroendocrine carcinoma (L-LCNEC) is a rare subset of lung carcinoma associated with poor overall survival. Due to its rarity, little has been established about its optimal treatment in the advanced stage. We report the case of a 41-year-old woman diagnosed with an unresectable locally advanced L-LCNEC who presented an impressive tumor response to immunotherapy with nivolumab after non-curative thoracic radiotherapy. Salvage surgery was then performed, and pathologic analysis of the resected piece revealed the absence of residual viable tumor cells. Based on this case report, we discuss the literature regarding the efficacy of inhibitors of programmed death-1 protein (PD-1) in L-LCNEC and their use in association with radiotherapy and in the neoadjuvant setting.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results